Finance

Lists
Outlook: 10.7% bullish·14.3% bearish
Go to analysis
RARE:NASDAQ
Ultragenyx Pharmaceutical Inc
$15.43
-0.90%
(-0.14) 1D
$15.43
0.00% (0.00)
After hours
Closed: Nov 6, 4:00:01 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RARE...
Open
$15.68
High
$15.97
Low
$15.12
Mkt. cap
1.52B
Avg. vol.
3.88M
Volume
4.05M
52-wk high
$39.89
52-wk low
$12.73
EPS
-$5.19
Beta
0.37
Shares outstanding
101.92M
No. of employees
1K
Open
$15.68
High
$15.97
Low
$15.12
Mkt. cap
1.52B
Avg. vol.
3.88M
Volume
4.05M
52-wk high
$39.89
52-wk low
$12.73
EPS
-$5.19
Beta
0.37
Shares outstanding
101.92M
No. of employees
1K
News stories
From web sources and news partners
Profile
Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases. Ultragenyx is based in Novato, CA and Brisbane, CA and has a presence in the Boston area, including a gene therapy plant under construction as of 2021. The company’s Latin American headquarters is located in Miami. Ultragenyx collaborates on product development with other companies including GeneTX, Kyowa Hakko Kirin, Mereo Biopharma and Daiichi Sankyo. Ultragenyx has three products Burosumab, Triheptanoin and Vestronidase alfa that have received FDA approval and several others currently in clinical trials. The company also holds the non-US commercial rights to Regeneron’s evinacumab-dgnb, which is approved by the FDA and EMA. Wikipedia
About Ultragenyx Pharmaceutical Inc
CEOEmil Kakkis
Employees1.37K
Founded2010
HeadquartersNovato, California, United States
SectorHealth Care
IndustryBiotechnology
Websiteultragenyx.com
Analyst ratings
Based on 20 analysts giving stock ratings to RARE in the past 3 months
Buy
Buy
9
Hold
11
Sell
0
12-month forecast
Based on 20 Wall Street analysts offering 12 month price targets for RARE in the last 3 months.
Highest
Current $15.43
$39.00 (+152.75%)
Average
$24.89 (+61.31%)
Lowest
$16.00 (+3.69%)
Analyst
Recommendation
Action
Price target
Projected
Date
Yigal Nochomovitz
Citi
Buy
Maintained
$22.00
+42.6%
11/06/2026
Joseph Schwartz
Leerink Partners
Buy
Reiterated
$33.00
+113.9%
11/05/2026
Allison Bratzel
Piper Sandler
Buy
Maintained
$36.00
+133.3%
11/05/2026
Ram Selvaraju
H.C. Wainwright
Buy
Reiterated
$25.00
+62%
11/06/2026
Eliana Merle
Barclays
Buy
Maintained
$32.00
+107.4%
11/05/2026
Kristen Kluska
Cantor Fitzgerald
Buy
Maintained
$39.00
+152.8%
11/03/2026
Yaron Werber
TD Cowen
Buy
Maintained
$19.00
+23.1%
11/04/2026
Luca Issi
RBC Capital
Hold
Maintained
$19.00
+23.1%
11/04/2026
Maxwell Skor
Morgan Stanley
Hold
Maintained
$22.00
+42.6%
11/04/2026
Laura Chico
Wedbush
Hold
Maintained
$22.00
+42.6%
11/04/2026
Whitney Ijem
Canaccord Genuity
Buy
Maintained
$34.00
+120.3%
11/04/2026
Benjamin Burnett
Wells Fargo
Hold
Maintained
$19.00
+23.1%
11/03/2026
Salveen Richter
Goldman Sachs
Hold
Maintained
$17.00
+10.2%
11/04/2026
Tazeen Ahmad
Bank of America Securities
Hold
Reiterated
$20.00
+29.6%
11/04/2026
Joon Lee
UBS
Hold
Initiated
$16.00
+3.7%
10/14/2026
Gavin Clark-Gartner
Evercore ISI
Hold
Maintained
$18.00
+16.7%
09/21/2026
Sami Corwin
William Blair
Hold
Maintained
-
-
09/18/2026
Maury Raycroft
Jefferies
Buy
Maintained
$28.00
+81.5%
09/03/2026
Anupam Rama
J.P. Morgan
Hold
Downgraded
$36.00
+133.3%
09/03/2026
Jack Allen
Robert W. Baird
Hold
Downgraded
$16.00
+3.7%
09/03/2026
Unknown Analyst
Jefferies
Buy
Maintained
$77.00
+399%
08/21/2026
Unknown Analyst
Wedbush
Hold
Maintained
$30.00
+94.4%
08/20/2026
Debjit Chattopadhyay
Guggenheim
Buy
Maintained
$35.00
+126.8%
08/03/2026
Last report
Nov 4, 2026
Fiscal period
Q3 2026
-$1.16 / -$0.75
-54.39%miss
Revenue / Est. (USD)
173.00M / 183.71M
-5.83%miss
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
207.28M
136.00M
214.00M
173.00M
Cost of goods sold
232.62M
189.00M
201.00M
186.00M
Cost of revenue
232.62M
189.00M
201.00M
186.00M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
87.94M
86.00M
88.00M
97.00M
Operating expense
87.94M
86.00M
88.00M
97.00M
Total operating expenses
320.56M
275.00M
289.00M
283.00M
Operating income
-113.28M
-139.00M
-75.00M
-110.00M
Other non operating income
-934.00K
-
1.00M
-
EBT including unusual items
-127.69M
-184.00M
-91.00M
-127.00M
EBT excluding unusual items
-127.17M
-154.00M
-91.00M
-127.00M
Income tax expense
870.00K
1.00M
1.00M
-9.00M
Effective tax rate
-0.68%
-0.54%
-1.10%
7.09%
Other operating expenses
-
-
-
-
Net income
-128.56M
-185.00M
-92.00M
-118.00M
Net profit margin
-62.02%
-136.03%
-42.99%
-68.21%
Earnings per share
-1.29
-1.54
-0.90
-1.16
Interest and investment income
6.51M
6.00M
5.00M
3.00M
Interest expense
-19.47M
-21.00M
-22.00M
-20.00M
Net interest expenses
-12.96M
-15.00M
-17.00M
-17.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
-104.50M
-131.00M
-67.00M
-101.00M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps